Targeted Oncology49m
Kato Breaks Down FDA Approval of Tislelizumab in Esophageal Cancer
Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma.
Sutro Biopharma (STRO) was downgraded to a Hold Rating at JMP Securities
Sutro Biopharma (STRO – Research Report) received a Hold rating and price target from JMP Securities analyst Reni Benjamin today. The ...
Targeted Oncology22h
Experts Discuss Tislelizumab’s FDA Approval in Esophageal Cancer
Ken Kato, MD, PhD, and Harry H. Yoon, MD, MHS, discussed the recent FDA approval of tislelizumab in the first line for patients with esophageal squamous cell carcinoma.